Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.

Illumina reported revenues of $1.10 billion ... to analyze genomes with unprecedented accuracy and completeness. PacBio reported revenues of $39.22 million, down 32.8% year on year, falling ...

In a report released yesterday, Eve Burstein from Bernstein maintained a Hold rating on Illumina (ILMN – Research Report), with a price target ...

PacBio to cut jobs, lower spending over NIH ... Activist investor Keith Meister to join Illumina's board Illumina said on Tuesday activist investor Keith Meister would join the gene-sequencing ...

Pacific Biosciences is reducing both headcount and spending across its DNA sequencing business, in the face of escalating global tariffs and threats to federal biomedical research grants. | Looking to ...

Analysts fell to the sidelines weighing in on Keros Therapeutics (KROS – Research Report) and Illumina (ILMN – Research Report) with neutral ...

Illumina ranks as the largest player in genetic sequencing. Other top genetic sequencing companies include PacBio, 10X Genomics, and Oxford Nanopore Technologies. Key findings are powered by ...

As it faces uncertainty in the research market at home and abroad, Illumina is making changes to its board of directors, bringing on an activist investor and installing a former FDA commissioner ...